Cardiovascular disease in end-stage renal disease

被引:2
|
作者
Park, Jung Tak [1 ]
Oh, Hyung Jung [1 ]
Kang, Shin-Wook [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源
关键词
Chronic kidney failure; Cardiovascular diseases; Risk factors; Biological markers; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; RECEIVING HEMODIALYSIS; CARDIAC BIOMARKERS; DIABETES-MELLITUS; RISK-FACTORS; DEATH RISK; FOLLOW-UP;
D O I
10.5124/jkma.2013.56.7.576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The number of end-stage renal disease (ESRD) patients is progressively growing with more than 60,000 ESRD patients on renal replacement therapy in Korea. The mortality risk in ESRD patients is approximately 10 to 20-fold higher compared to the general population, which is mainly attributed to prevalent cardiovascular disease in these patients. However, the risk factors for cardiovascular disease in ESRD patients are different from the general population, and useful biomarkers for predicting cardiovascular mortality are not completely defined. The nationwide multicenter Clinical Research Center (CRC) for ESRD program was initiated in Korea not only to elucidate the incidence and prevalence of cardiovascular disease in ESRD patients but also to identify potential risk factors including various biomarkers for cardiovascular disease. A prospective cohort of 864 incident hemodialysis patients, from 34 dialysis centers of the CRC for ESRD in Korea, was followed up for 36 months, and the clinical outcome of these patients was reviewed. This article presents the recent data from the CRC for ESRD program, and, in addition, brief reviews on key risk factors and potential biomarkers for cardiovascular disease in ESRD patients.
引用
收藏
页码:576 / 582
页数:7
相关论文
共 50 条
  • [41] End-stage renal disease in Fabry disease
    Granata, A.
    Romeo, G.
    Gulisano, S.
    Leonardi, G.
    Romano, R.
    Manca, E.
    Fiumara, A.
    Sicurezza, E.
    CLINICAL THERAPEUTICS, 2007, 29 : S20 - S20
  • [42] The Prevalence and Types of Cardiovascular Disease in Patients With End-Stage Renal Disease Undergoing Renal Transplantation
    Bozbas, H.
    Altin, C.
    Karacaglar, E.
    Kanyilmaz, S.
    Yildirir, A.
    Muderrisoglu, H.
    Haberal, M.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (10) : 3478 - 3480
  • [43] Putting an end to end-stage renal disease
    Setness, PA
    POSTGRADUATE MEDICINE, 2000, 108 (01) : 11 - 11
  • [44] SPECT in End-Stage Renal Disease
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (09) : 26N - 27N
  • [45] Thrombosis in end-stage renal disease
    Casserly, LF
    Dember, LM
    SEMINARS IN DIALYSIS, 2003, 16 (03) : 245 - 256
  • [46] Lipids in end-stage renal disease
    Wanner, C
    JOURNAL OF NEPHROLOGY, 2002, 15 (02) : 202 - 204
  • [47] Osteoporosis in end-stage renal disease
    Lindberg, JS
    Moe, SM
    SEMINARS IN NEPHROLOGY, 1999, 19 (02) : 115 - 122
  • [48] Adiponectin and end-stage renal disease
    Markaki, Anastasia
    Psylinakis, Emmanuel
    Spyridaki, Aspasia
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (03): : 345 - 354
  • [49] Keloids and end-stage renal disease
    Freedman, BI
    Morrow, MA
    Tuttle, AB
    Igwemezie, BM
    Rich, SS
    Sherertz, EF
    Tuttlea, FNAJANAEB
    NEPHRON, 1998, 80 (02): : 244 - 246
  • [50] Hypertension in end-stage renal disease
    Martínez-Maldonado, M
    KIDNEY INTERNATIONAL, 1998, 54 : S67 - S72